JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jin, H.
Right arrow Articles by Paoni, N. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jin, H.
Right arrow Articles by Paoni, N. F.

CARDIOVASCULAR

Early Treatment with Hepatocyte Growth Factor Improves Cardiac Function in Experimental Heart Failure Induced by Myocardial Infarction

Hongkui Jin, Renhui Yang, Wei Li, Annie K. Ogasawara, Ralph Schwall, David A. Eberhard, Zhong Zheng, David Kahn, and Nicholas F. Paoni

Departments of Cardiovascular Research (H.J., R.Y., W.L., R.K.O., N.F.P.), Molecular Oncology (R.S., Z.Z.), Pathology (D.A.E.), and Recovery Science (D.K.), Genentech, Inc., South San Francisco, California

Plasma levels of hepatocyte growth factor (HGF) are increased within hours of cardiac ischemia/reperfusion in rats, and HGF has been shown to be cardioprotective toward acute ischemic injury. Myocardial levels of HGF mRNA and protein are increased for several days after myocardial infarction (MI), however, indicating a possible additional protective effect of HGF toward the progression of MI to heart failure. The purpose of this study was to determine whether HGF administration during the time course of endogenous cardiac HGF induction would lead to long-term improvement in cardiac function in rats with MI. MI was induced by 2-h occlusion of the left coronary artery, followed by reperfusion. HGF was given by intravenous infusion at 0.45 mg/kg/day for 6 days beginning on the day after surgery. Cardiac function and hemodynamic parameters were measured by using indwelling catheters and perivascular flow probes in conscious animals 8 weeks post-MI. Myocardial infarcts were approximately 30% of the left ventricle, and there was no difference in infarct size between the vehicle-treated and HGF-treated groups. Compared with untreated sham-operated rats, vehicle-treated MI animals had significantly lower cardiac index and stroke volume index and higher systemic vascular resistance, indicating heart failure developed. Treatment with HGF caused a significant increase in cardiac index and stroke volume index and a reduction in systemic vascular resistance in rats with MI, restoring these parameters close to those observed in sham-operated control animals. These results provide direct evidence that HGF may be of benefit to cardiovascular function in ischemic cardiomyopthy.


Received July 31, 2002; accepted October 24, 2002.

Address correspondence to: Dr. Hongkui Jin, Department of Cardiovascular Research, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080. E-mail address: hkj{at}gene.com




This article has been cited by other articles:


Home page
Eur. J. Cardiothorac. Surg.Home page
K. R. Cho, J.-S. Choi, W. Hahn, D. S. Kim, J. S. Park, D. S. Lee, and K.-B. Kim
Therapeutic angiogenesis using naked DNA expressing two isoforms of the hepatocyte growth factor in a porcine acute myocardial infarction model
Eur. J. Cardiothorac. Surg., October 1, 2008; 34(4): 857 - 863.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
R. R. Edelman
Can MR Imaging Be Used to Determine the Efficacy of Gene Therapy in the Heart?
Radiology, October 1, 2008; 249(1): 1 - 2.
[Full Text] [PDF]


Home page
Circ. Res.Home page
N. A. Gude, G. Emmanuel, W. Wu, C. T. Cottage, K. Fischer, P. Quijada, J. A. Muraski, R. Alvarez, M. Rubio, E. Schaefer, et al.
Activation of Notch-Mediated Protective Signaling in the Myocardium
Circ. Res., May 9, 2008; 102(9): 1025 - 1035.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
G. Athauda, A. Giubellino, J. A. Coleman, C. Horak, P. S. Steeg, M.-J. Lee, J. Trepel, J. Wimberly, J. Sun, A. Coxon, et al.
c-Met Ectodomain Shedding Rate Correlates with Malignant Potential.
Clin. Cancer Res., July 15, 2006; 12(14): 4154 - 4162.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
W. Wojakowski, M. Tendera, A. Michalowska, M. Majka, M. Kucia, K. Maslankiewicz, R. Wyderka, A. Ochala, and M. Z. Ratajczak
Mobilization of CD34/CXCR4+, CD34/CD117+, c-met+ Stem Cells, and Mononuclear Cells Expressing Early Cardiac, Muscle, and Endothelial Markers Into Peripheral Blood in Patients With Acute Myocardial Infarction
Circulation, November 16, 2004; 110(20): 3213 - 3220.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. Borowiak, A. N. Garratt, T. Wustefeld, M. Strehle, C. Trautwein, and C. Birchmeier
Met provides essential signals for liver regeneration
PNAS, July 20, 2004; 101(29): 10608 - 10613.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.